通过综合生物信息学和机器学习识别糖尿病心肌病中的脂肪酸代谢基因特征
Aoyun Wei1, Haozhi Zhang2, Oudie He2
1Division of Medical Technology, Tianjin Medical University, Tianjin, 300203, China; Department of Clinical Laboratory, Tianjin Medical University Baodi Hospital, Tianjin, 301800, China.
Biochemical and biophysical research communications
|February 26, 2026
概括
糖尿病心肌病 (DCM) 涉及多个基因,包括Ech1和Fbp2. 这项研究确定了关键的基因和代谢变化,为DCM诊断和治疗提供了新的目标.
科学领域:
- 心血管生物学 心血管生物学
- 代谢障碍 代谢障碍 代谢障碍
- 基因组学就是基因组学.
背景情况:
- 糖尿病心肌病 (DCM) 是糖尿病的一个严重并发症,导致心力衰竭和死亡率.
- 确切的遗传原因和DCM的分子机制仍然不完全理解.
研究的目的:
- 确定关键的基因和参与糖尿病心肌病变的发病过程中的分子途径.
- 探索DCM潜在的诊断标记和治疗点.
主要方法:
- 使用差异表达式分析,PPI网络和机器学习,对七个基因表达综合 (GEO) 数据集的综合分析.
- 在DCM小鼠模型中使用RT-qPCR,Western blot,单核RNA-seq和多omics分析 (RNA-seq,蛋白质组,代谢组) 的验证结果.
主要成果:
- 在DCM中确定了七个上调基因:Hmgcs2,Ech1,Acot2,Acot1,Fbp2,Fkbp5和Decr1,主要在心肌细胞中.
- 在DCM小鼠心脏中证实了Ech1,Fbp2和Acot1的mRNA和蛋白质水平的增加.
- 观察到尼古丁胺胺二核酸和循环ADP-ribose的减少,以及DCM心肌组织中自由脂肪酸的增加,表明脂肪酸代谢增强.
结论:
- Ech1和Fbp2在糖尿病心肌病的发展和进展中起着至关重要的作用.
- 这些基因代表了DCM诊断和治疗的新型分子标,提供了新的研究途径.
相关概念视频
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...